Orthopaedic & Rheumatologic Institute Outcomes
Surgical Quality Improvement
Total Hip Arthroplasty Outcomes
Total Hip Arthroplasty ACS NSQIP Outcomes
January 1, 2024 – December 31, 2024
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall total hip arthroplasty ACS NSQIP performance benchmarked against 491 participating sites.
Total Hip Arthroplasty (491 sites) | N | Observed | Expected |
---|---|---|---|
30 Day Mortality | 250 | 0.00% | 0.39% |
30 Day Morbidity | 250 | 3.60% | 4.17% |
Cardiac | 250 | 0.40% | 0.20% |
Pneumonia | 250 | 0.00% | 0.35% |
Unplanned Intubation | 250 | 0.00% | 0.10% |
Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 250 | 0.80% | 0.58% |
Renal Failure | 250 | 0.00% | 0.31% |
Urinary Tract Infection (UTI) | 250 | 0.80% | 0.74% |
Surgical Site Infection (SSI) | 250 | 1.60% | 1.58% |
Sepsis | 250 | 0.40% | 0.41% |
Unplanned Reoperation | 250 | 2.40% | 2.58% |
Unplanned Readmission | 250 | 4.40% | 4.64% |
American College of Surgeons National Surgical Quality Improvement Program, 2025.
ACS NSQIP® Semiannual Report July, 2025, Chicago: American College of Surgeons.